Zymeworks Quote - ZYME

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

13.88

Bid

12.29

Ask

14.11

Volume

323,783

13.58 Day's Range 14.13

7.97 52 Week Range 17.70

Market Cap

956.02M

Previous Close

13.99

Open

14.11

Last Trade

13.2

Last Trade Time

Financial Volume

US$ 4,488,393

VWAP

13.8623

Average Volume (3m)

526,667

Shares Outstanding

68,877,526

Dividend Yield

PE Ratio

-8.06

Earnings Per Share (EPS)

-1.72

Revenue

76.01M

Net Profit

-118.67M

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiat... Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.zymeworks.com

Headquarters

Wilmington, Delaware, USA

Founded

Zymeworks Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZYME. The last closing price for Zymeworks was US$13.99. Over the last year, Zymeworks shares have traded in a share price range of US$ 7.97 to US$ 17.70.

Zymeworks currently has 68,877,526 shares outstanding. The market capitalization of Zymeworks is US$963.60 million. Zymeworks has a price to earnings ratio (PE ratio) of -8.06.

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025IND applications for initiating first-in-human studies for...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy 18 months ahead of original targetNomination of ZW209, a novel trispecific T...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.11	0.79883805374	13.77	14.63	12.8	562870	13.72491042	CS
4	0.6	4.51807228916	13.28	16.5065	12.8	551786	14.22773676	CS
12	0.9	6.93374422188	12.98	17.7	12.39	526667	14.38377146	CS
26	3.57	34.6265761397	10.31	17.7	9.405	600893	12.62078597	CS
52	3.45	33.0776605944	10.43	17.7	7.97	603552	11.21030255	CS
156	7.5	117.554858934	6.38	17.7	6.015	618611	9.70584301	CS
260	7.5	117.554858934	6.38	17.7	6.015	618611	9.70584301	CS

ZYME - Frequently Asked Questions (FAQ)

What is the current Zymeworks share price?

The current share price of Zymeworks is US$ 13.88

How many Zymeworks shares are in issue?

Zymeworks has 68,877,526 shares in issue

What is the market cap of Zymeworks?

The market capitalisation of Zymeworks is USD 963.6M

What is the 1 year trading range for Zymeworks share price?

Zymeworks has traded in the range of US$ 7.97 to US$ 17.70 during the past year

What is the PE ratio of Zymeworks?

The price to earnings ratio of Zymeworks is -8.06

What is the cash to sales ratio of Zymeworks?

The cash to sales ratio of Zymeworks is 12.58

What is the reporting currency for Zymeworks?

Zymeworks reports financial results in USD

What is the latest annual turnover for Zymeworks?

The latest annual turnover of Zymeworks is USD 76.01M

What is the latest annual profit for Zymeworks?

The latest annual profit of Zymeworks is USD -118.67M

What is the registered address of Zymeworks?

The registered address for Zymeworks is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Zymeworks website address?

The website address for Zymeworks is www.zymeworks.com

Which industry sector does Zymeworks operate in?

Zymeworks operates in the PHARMACEUTICAL PREPARATIONS sector

Symbol	Price	Vol.
BTCTBTC Digital Ltd	US$ 8.2697 (73.73%)	61.45M
BDMDBaird Medical Investment Holdings Ltd	US$ 8.80 (62.36%)	18.63M
CRKNCrown Electrokinetics Corporation	US$ 0.1235 (54.96%)	764.86M
NUKKNukkleus Inc	US$ 29.97 (45.98%)	19.09M
GSITGSI Technology	US$ 3.97 (44.36%)	87.7M
DOGZDogness International Corporation	US$ 18.23 (-58.77%)	740.45k
ORKTOrangeKloud Technology Inc	US$ 3.02 (-24.88%)	21.08M
PMAXPowell Max Ltd	US$ 0.6364 (-23.31%)	4.17M
LGCBLinkage Global Inc	US$ 0.2876 (-22.27%)	890.66k
YYAIConnexa Sports Technologies Inc	US$ 0.8299 (-20.20%)	602.48k
CRKNCrown Electrokinetics Corporation	US$ 0.1235 (54.96%)	764.86M
GCTKGlucoTrack Inc	US$ 0.0852 (15.45%)	465.22M
RIMEAlgorhythm Holdings Inc	US$ 0.0406 (-4.02%)	387.23M
TGLTreasure Global Inc	US$ 0.2459 (14.75%)	267.1M
NVDANVIDIA Corporation	US$ 137.71 (3.10%)	201.4M

Symbol

Price

Vol.